Skip to main content

ORIGINAL RESEARCH article

Front. Cell. Infect. Microbiol.
Sec. Biofilms
Volume 14 - 2024 | doi: 10.3389/fcimb.2024.1403219
This article is part of the Research Topic Fighting Microbial Biofilms: Novel Therapeutics and Antibiofilm Strategies View all 3 articles

Proven Anti-virulence Therapies in Combating Methicillin and Vancomycin Resistant Staphylococcus aureus Infections

Provisionally accepted
  • 1 Beni-Suef University, Beni-Suef, Beni-Suef, Egypt
  • 2 Faculty of Science, Al Azhar University, Cairo, Beni Suef, Egypt
  • 3 Modern University for Information and Technology, Cairo, Cairo, Egypt
  • 4 Alexandria University, Alexandria, Alexandria, Egypt
  • 5 Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia
  • 6 College of Pharmacy, Al Maaref University College, Ramadi, Al Anbar, Iraq
  • 7 Port Said University, Port Said, Egypt

The final, formatted version of the article will be published soon.

    Despite years of efforts to develop new antibiotics for eradicating multidrug-resistant (MDR) and multi-virulent Methicillin-Resistant Staphylococcus aureus (MRSA) and Vancomycin-Resistant Staphylococcus aureus (VRSA) infections, treatment failures and poor prognoses in most cases have been common. Therefore, there is an urgent need for new therapeutic approaches targeting virulence arrays. Our aim is to discover new anti-virulence therapies targeting MRSA and VRSA virulence arrays. We employed phenotypic, molecular docking, and genetic studies to screen for anti-virulence activities among selected promising compounds: Coumarin, Simvastatin, and Ibuprofen. We found that nearly all detected MRSA and VRSA strains exhibited MDR and multi-virulent profiles. The molecular docking results aligned with the phenotypic and genetic assessments of virulence production. Biofilm and hemolysin productions were inhibited, and all virulence genes were downregulated upon treatment with sub-minimum inhibitory concentration (sub-MIC) of these promising compounds.Ibuprofen was the most active compound, exhibiting the highest inhibition and downregulation of virulence gene products. Moreover, in vivo and histopathological studies confirmed these results. Interestingly, we observed a significant decrease in wound area and improvements in re-epithelialization and tissue organization in the Ibuprofen and antimicrobial treated group compared to the antimicrobial treated group alone. These findings support the idea that a combination of Ibuprofen and antimicrobial drugs may offer a promising new therapy for MRSA and VRSA infections. We hope that our findings can be implemented in clinical practice to assist physicians in making the most suitable treatment decisions.

    Keywords: anti-virulence, Histopathological, molecular docking, Coumarin, Simvastatin, Ibuprofen

    Received: 19 Mar 2024; Accepted: 04 Jul 2024.

    Copyright: © 2024 Bakeer, Gaafar, El-Gendy, El Badry, G.Khalil, Mansour, Alharbi, Selim and Bendary. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Mahmoud M. Bendary, Port Said University, Port Said, Egypt

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.